K S Boockvar1, S Liu, N Goldstein, J Nebeker, A Siu, T Fried. 1. Geriatric Research, Education, and Clinical Center, James J Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA. kenneth.boockvar@mssm.edu
Abstract
BACKGROUND: Medication-prescribing discrepancies are used as a quality measure for patients transferred between sites of care. The objective of this study was to quantify the rate of adverse drug events (ADEs) caused by prescribing discrepancies and the discrimination of an index of high-risk transition drug prescribing. METHODS: We examined medical records of patients transferred between seven nursing homes and three hospitals between 1999 and 2005 in New York and Connecticut for transfer-associated prescribing discrepancies. ADEs caused by discrepancies were determined by two clinician raters. We calculated the fraction of medication discrepancies that caused ADEs in each of 22 drug classes by calculating positive predictive values (PPVs). We calculated the discrimination of a count of high-risk drug discrepancies, selected from published lists of high-risk medications and using observed PPVs. RESULTS: 208 patients were hospitalised 304 times. Overall, 65 of 1350 prescribing discrepancies caused ADEs, for a PPV of 0.048 (95% CI 0.037 to 0.061). PPVs by drug class ranged from 0 to 0.28. Drug classes with the highest PPVs were opioid analgesics, metronidazole, and non-opioid analgesics. Patients with 0, 1-2 and >/=3 high-risk discrepancies had a 13%, 23% and 47% chance of experiencing a discrepancy-related ADE, respectively. CONCLUSIONS: Discrepancies in certain drug classes more often caused ADEs than other types of discrepancies in hospitalised nursing-home patients. Information about ADEs caused by medication discrepancies can be used to enhance measurement of care quality, identify high-risk patients and inform the development of decision-support tools at the time of patient transfer.
BACKGROUND: Medication-prescribing discrepancies are used as a quality measure for patients transferred between sites of care. The objective of this study was to quantify the rate of adverse drug events (ADEs) caused by prescribing discrepancies and the discrimination of an index of high-risk transition drug prescribing. METHODS: We examined medical records of patients transferred between seven nursing homes and three hospitals between 1999 and 2005 in New York and Connecticut for transfer-associated prescribing discrepancies. ADEs caused by discrepancies were determined by two clinician raters. We calculated the fraction of medication discrepancies that caused ADEs in each of 22 drug classes by calculating positive predictive values (PPVs). We calculated the discrimination of a count of high-risk drug discrepancies, selected from published lists of high-risk medications and using observed PPVs. RESULTS: 208 patients were hospitalised 304 times. Overall, 65 of 1350 prescribing discrepancies caused ADEs, for a PPV of 0.048 (95% CI 0.037 to 0.061). PPVs by drug class ranged from 0 to 0.28. Drug classes with the highest PPVs were opioid analgesics, metronidazole, and non-opioid analgesics. Patients with 0, 1-2 and >/=3 high-risk discrepancies had a 13%, 23% and 47% chance of experiencing a discrepancy-related ADE, respectively. CONCLUSIONS: Discrepancies in certain drug classes more often caused ADEs than other types of discrepancies in hospitalised nursing-home patients. Information about ADEs caused by medication discrepancies can be used to enhance measurement of care quality, identify high-risk patients and inform the development of decision-support tools at the time of patient transfer.
Authors: Peter M Layde; Leslie M Cortes; Stephen P Teret; Karen J Brasel; Evelyn M Kuhn; James A Mercy; Stephen W Hargarten; Leslie A Maas Journal: JAMA Date: 2002-04-17 Impact factor: 56.272
Authors: J H Gurwitz; T S Field; J Avorn; D McCormick; S Jain; M Eckler; M Benser; A C Edmondson; D W Bates Journal: Am J Med Date: 2000-08-01 Impact factor: 4.965
Authors: Jonathan R Nebeker; Paul R Yarnold; Robert C Soltysik; Brian C Sauer; Shannon A Sims; Matthew H Samore; Randall W Rupper; Kathleen M Swanson; Lucy A Savitz; Judith Shinogle; Wu Xu Journal: Med Care Date: 2007-10 Impact factor: 2.983
Authors: Steven M Handler; Richard L Altman; Subashan Perera; Joseph T Hanlon; Stephanie A Studenski; James E Bost; Melissa I Saul; Douglas B Fridsma Journal: J Am Med Inform Assoc Date: 2007-04-25 Impact factor: 4.497
Authors: Tamasine C Grimes; Catherine A Duggan; Tim P Delaney; Ian M Graham; Kevin C Conlon; Evelyn Deasy; Marie-Claire Jago-Byrne; Paul O' Brien Journal: Br J Clin Pharmacol Date: 2011-03 Impact factor: 4.335
Authors: David G Stevenson; Stacie B Dusetzina; A James O'Malley; Susan L Mitchell; Barbara J Zarowitz; Michael E Chernew; Joseph P Newhouse; Haiden A Huskamp Journal: Med Care Date: 2014-10 Impact factor: 2.983
Authors: Xavier Pourrat; Hélène Corneau; Stéphanie Floch; Marie Pierre Kuzzay; Luc Favard; Philippe Rosset; Nicolas Hay; Jacqueline Grassin Journal: Int J Clin Pharm Date: 2013-05-18